Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus
Go back to Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 63.83 -0.82 (1.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $64.65 | 52 Week High | $77.12 | |||
| Open | $64.13 | 52 Week Low | $49.03 | |||
| Day High | $64.33 | P/E | 41.45 | |||
| Day Low | $63.35 | EPS | $1.54 | |||
| Volume | 7,529,798 | |||||
